PolyI:C, a synthetic double-stranded RNA analog, acts as an immune-enhancing adjuvant that regresses tumors in cytotoxic T lymphocyte (CTL)-dependent and CTL-independent manner, the latter of which remains largely unknown. + Ly6G + cells that had been activated with polyI:C showed cytotoxicity and inhibited tumor growth through the production of reactive oxygen species (ROS)/reactive nitrogen species (RNS). These responses were abolished in either Toll/interleukin-1 receptor domain-containing adaptor molecule-1 (TICAM-1) − / − or interferon (IFN)-αβ receptor 1 (IFNAR1) − / − mice. Thus, our results suggest that polyI:C activates the TLR3/TICAM-1 and IFNAR signaling pathways in CD11b + Ly6G + cells in tumors, thereby eliciting their antitumor activity, independent of those in CD8α + / CD103 + DCs that prime CTLs.
1
PolyI:C, a synthetic double-stranded RNA analog, acts as an immune-enhancing adjuvant that regresses tumors in cytotoxic T lymphocyte (CTL)-dependent and CTL-independent manner, the latter of which remains largely unknown. Tumors contain CD11b + Ly6G + cells, known as granulocytic myeloid-derived suppressor cells (G-MDSCs) or tumor-associated neutrophils (TANs) that play a critical role in tumor progression and development. Here, we demonstrate that CD11b + Ly6G + cells respond to polyI:C and exhibit tumoricidal activity in an EL4 tumor implant model. PolyI:C-induced inhibition of tumor growth was attributed to caspase-8/3 cascade activation in tumor cells that occurred independently of CD8α + /CD103 + dendritic cells (DCs) and CTLs. CD11b + Ly6G + cells was essential for the antitumor effect because depletion of CD11b + Ly6G + cells totally abrogated tumor regression and caspase activation after polyI:C treatment. CD11b + Ly6G + cells that had been activated with polyI:C showed cytotoxicity and inhibited tumor growth through the production of reactive oxygen species (ROS)/reactive nitrogen species (RNS). These responses were abolished in either Toll/interleukin-1 receptor domain-containing adaptor molecule-1 (TICAM-1)
− / − or interferon (IFN)-αβ receptor 1 (IFNAR1)
− / − mice. Thus, our results suggest that polyI:C activates the TLR3/TICAM-1 and IFNAR signaling pathways in CD11b + Ly6G + cells in tumors, thereby eliciting their antitumor activity, independent of those in CD8α + / CD103 + DCs that prime CTLs. Cell Death and Differentiation (2017) 24, 385-396; doi:10.1038/cdd.2016.131; published online 11 November 2016 Immune cells are implicated in the regulation of tumor growth. 1, 2 Myeloid-derived cells, such as macrophages and dendritic cells (DCs), express Toll-like receptors (TLRs) and participate in the formation of tumor-progressive or tumorsuppressive microenvironments in response to patternrecognition receptor (PRR) stimuli. Intratumor myeloid cells phagocytose tumor debris containing tumor-associated antigens (TAAs) to prime antigen-specific cytotoxic T lymphocytes (CTLs) together with released cytokines. 2 Although CTLs are critical for tumor regression, tumor cells do not always generate neoantigens or present TAAs. 3, 4 Even under the conditions where CTLs no longer participate in tumor elimination, TLR ligands often induce a tumor-regressive response. Therefore, a CTL-independent antitumor event occurs via stimulation of TLRs in tumor-associated myeloid cells during immunotherapy with TLR ligands. The mechanism of this antitumor response remains largely undetermined.
PolyI:C, a synthetic double-stranded RNA (dsRNA) analog, induces type-I interferon (IFN) production and fosters CD8α + / CD103 + DC maturation, leading to tumor growth inhibition mediated by natural killer (NK) cells and CTLs in mice. 5, 6 In either case, polyI:C activates TLR3 in endosomes. 7 TLR3 activates Toll/interleukin-1 receptor domain-containing adaptor molecule-1 (TICAM-1) that evokes the production of type-I IFNs and proinflammatory cytokines. 8 PolyI:C additionally activates the melanoma differentiation-associated gene 5 (MDA5)-mitochondrial antiviral-signaling protein (MAVS) pathway that induces a systemic IFN/cytokine production. 9 These pathways are conserved in most myeloid cells.
Myeloid-derived cells are abnormally accumulated in tumorbearing hosts. CD11b + Ly6G + cells represent a population of tumor-supporting myeloid cells in mice. 10 They accumulate in tumors and blood/lymphoid organs and promote tumor growth, metastasis, angiogenesis, and immunosuppression. [11] [12] [13] [14] CD11b +
Ly6G
+ cells are identified as granulocytic myeloidderived suppressor cells (G-MDSCs) or as tumor-associated neutrophils (TANs). 10 G-MDSCs and TANs show morphological and functional similarities to neutrophils. 15 In patients, neutrophil infiltration into a tumor is correlated with poor prognosis. 16, 17 G-MDSCs preferentially produce reactive oxygen species/ reactive nitrogen species (ROS/RNS) including hydrogen peroxide (H 2 O 2 ) and peroxynitrite (PNT). PNT is responsible for the suppression of T cell-mediated antitumor immunity by G-MDSCs. [18] [19] [20] [21] Consequently, these suppression mechanisms enable tumor cells to escape tumor antigen-specific CTLs. However, emerging evidence has revealed that functionally polarized neutrophils induced by cytokines, chemokines, or growth factors inhibit tumor growth and metastasis. 22 
Ly6C
high monocytic MDSCs (M-MDSCs). [26] [27] [28] We have previously demonstrated that a polyI:C-induced TLR3/TICAM-1 signal induces tumoricidal activity in tumorassociated macrophages (TAMs), leading to tumor growth inhibition in 3LL tumor-bearing mice. 29 In this study, using an EL4 tumor model, we found that CD11b + Ly6G
+ cells inhibit tumor growth upon polyI:C treatment even if tumor cells are out of targets of CTL, NK, and M1 TAM-mediated cytolysis.
Results
Inhibition of tumor growth by polyI:C treatment through the TICAM-1 signaling pathway. The growth of EL4 tumors in mice was significantly retarded by polyI:C administration ( Figure 1a) . To analyze the host signaling pathway involved in this tumor growth inhibition, EL4 cells were implanted into mice deficient for TICAM-1 or MAVS that are downstream adapter molecules of TLR3 or MDA5, respectively. The polyI: C-induced inhibition of tumor growth was abrogated in TICAM-1 − / − but not MAVS − / − mice ( Figure 1a) . PoyI:C induces type-I IFN production, and the inhibition of EL4 tumor growth was abrogated in IFNAR1 − / − mice. Thus, polyI:C treatment led to the inhibition of EL4 tumor growth via the TLR3/TICAM-1 and type-I IFN signaling pathways. EL4 cells express MHC class-I (H-2D  b and H-2K   b   ) , CD3ε, CD28, PD-1, and PD-L1, but not MHC class-II (I-Ab), CD4, CD8, CD11b, CD11c, and CTLA-4 (Supplementary Table 1 ). EG7 cells expressing a model TAA (OVA protein) are a CTL-sensitive cell line derived from EL4 cells. However, polyI:C-induced inhibition of EL4 tumor growth was not abrogated by pretreatment of mice with antibodies (Abs) against CD8β, CD4, or NK1.1 (Figure 1b) .
PolyI:C treatment robustly increased TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling)-positive cells, suggesting that apoptosis or necrosis occurred in the tumor (Figure 1c ). Cleaved caspase-3, an apoptosis marker, 30, 31 was increased throughout the tumors after polyI: C treatment; this effect was abrogated in TICAM-1 − / − and IFNAR1 − / − , but not MAVS − / − mice (Figure 1d ). Caspase-3 activation is induced by caspase-8, 9, or 12.
31 Cleaved caspase-8 was increased in tumor at 7 and 18 h after polyI:C injection (Figures 1e and f) . The full-length caspase-9 slightly decreased and the amount of full-length caspase-12 was unchanged. These data suggest that polyI:C treatment induces apoptosis of EL4 tumor cells through the caspase-8/3 cascade, resulting in tumor growth inhibition. The TLR3/ TICAM-1 pathway triggers apoptosis in cancer cells through caspase-8 activation. 32 However, EL4 cells are insensitive to direct stimulation with polyI:C. 33 The polyI:C-induced caspase-3 activation in tumors occurred in Batf3 − / − mice that lack CD8α + /CD103 + DC subsets 34 ( Supplementary Figure 1) . Taken together, the CD8α + /CD103 + DC-mediated NK and CTL induction is unlikely involved in the inhibition of EL4 tumor growth. That is, previously unidentified cells and/or mechanisms could participate in the therapeutic potential of polyI:C in the EL4-implant model. Figure 3a) (Figure 2d , upper). In contrast, tumor growth was significantly delayed when EL4 cells Figure 4a) . TNF-α does not induce cell death of EL4 cells. 29 We observed that in vivo and in vitro polyI:C treatment increased mRNA expression of TRAIL in CD11b ROS/RNS induce caspase-8/3 activation and EL4 cell death. ROS/RNS, including PNT and H 2 O 2 , induce apoptosis of cancer cells. 38 When added exogenously, these + cells in tumor-bearing mice that was dependent on the TICAM-1 pathway (Supplementary Figure 3a) . Recombinant type-I IFNs increased the production of ROS/ RNS by CD11b + Ly6G
+ cells (Supplementary Figure 7) . Tumor-infiltrating CD11b + Ly6G + cells also showed enhanced H 2 O 2 production after polyI:C treatment (Figure 4h ). + cells is critical for their antitumor activity.
PNT and H 2 O 2 induce caspase-8/3 activation and cell death in cancer cell lines. We investigated whether CD11b + Ly6G + cells were generally important for tumor growth inhibition by polyI:C treatment using another tumor model. Inhibition of B16 tumor growth is largely dependent on NK cells in polyI:C therapy. 5 The inhibitory effect of polyI:C on B16 tumor growth was partially abrogated in mice pretreated with an anti-Ly6G Ab (Figure 6a ). CD11b 
Ly6G
+ cells activated by polyI:C inhibited B16 tumor growth (Figure 6b) . Furthermore, polyI:C induced ROS/RNS production from CD11b + Ly6G
+ cells in tumor and spleen of mice implanted with B16, and also 3LL, and MC38 cells (Figure 6c and Supplementary Figure 8) .
Next, to determine whether ROS/RNS induce caspase-8/3 activation and cytotoxicity in those cancer cell lines, we treated them with PNT and examined the cytotoxicity (Figure 6d (Figures 4f and 7a) . Cancer cell-derived factors appear to modulate neutrophil function. 43 Thus, PNT levels in CD11b 
+ cells alone (Figure 7a ). EL4 cells secrete granulocyte macrophage colony-stimulating factor (GM-CSF), a survival factor of G-MDSCs or neutrophils. 44 However, in the presence of recombinant GM-CSF, polyI:C stimulation did not significantly increase PNT production by CD11b + Ly6G
+ cells, although the basal levels of ROS/RNS production were increased (Figure 7a ). EL4 cells failed to enhance PNT production by CD11b + Ly6G
+ cells in a transwell, suggesting that cell-to-cell contact is required for this activity (Figure 7b) . Thus, EL4 cells enhance ROS/RNS production by CD11b 45, 46 TLRs could become targets for altering the phenotype of intratumor myeloid cells. 47, 48 MDSCs express an array of TLRs and their activation affects expansion and function of MDSCs. TLR2 or TLR4 activation in MDSCs may accelerate the development of immunosuppressive conditions. 48, 49 In contrast, activation of TLR9, TLR3, or MDA5 abolishes the suppressive activity of MDSCs and may contribute to tumor growth inhibition. [26] [27] [28] In this study, we demonstrate that TICAM-1 is a critical adapter that determines the antitumor 
+ Ly6G + cells in RNA adjuvant therapy, and that both TICAM-1-inducible genes and TICAM-1-induced type-I IFNs are important for this antitumor mechanism. In combination with our previous data, we propose that myeloid cells expanded in cancer contribute to tumor growth inhibition, particularly under an RNA adjuvant treatment, rather than preventing the therapeutic effects through their immunosuppressive activity. This could be achieved by functional alteration of tumor-associated myeloid cells to exhibit tumorkilling activity. In this context, an RNA adjuvant can induce tumor regression even if immunosuppressive myeloid cells abundantly accumulate in tumors, such that the CTL response is insufficient to regress the tumor.
We found that the caspase-8/3 cascade is specifically activated in tumors after polyI:C treatment. Excessive amounts of extrinsic ROS/RNS induce caspase-8/3 activation in cancer cells, leading to apoptosis. 40, 41 We show that CD11b 
+ cells was abrogated by treatment of mice with uric acid or iNOS inhibitors. Because these reagents neutralize a broad range of ROS/RNS, other ROS/RNS may be synergistically involved in this cytotoxic effect. [50] [51] [52] We demonstrate that ROS/RNS production by CD11b + Ly6G
+ cells requires the activation of TICAM-1/IFNAR signaling pathways. This response is partly mediated by TICAM-1-regulated induction of iNOS (NOS2) and NOX2 (Cybb) mRNA expression. ROS/RNS production is regulated by not only iNOS and NOX2 gene expression but also by protein-protein interactions in the TLR3/TICAM-1 signaling pathway. [53] [54] [55] Furthermore, our data indicate that TICAM-1-dependent type-I IFN production is critical for ROS/RNS production as well as tumor growth inhibition by CD11b + Ly6G + cells. The TICAM-1 and IFNAR pathways may cooperatively regulate the expression and activation of iNOS and NADPH oxidase complex. Further studies are required to identify the critical factor to control ROS/RNS production triggered by the TICAM-1/IFNAR pathway in CD11b + Ly6G + cells. Activation of TLR3/TICAM-1 pathway induces multifarious effector mechanisms for tumor regression in which NK cells, CTLs, and M1-shifted TAMs are involved. 5, 6, 29 In this study, we further identified CD11b + Ly6G + cells as a tumoricidal effector. As dsRNA treatment simultaneously induces activation of these effector cells, the sensitivity of cancer cells to the effector molecules ultimately determines each effector cell-mediated tumor clearance. Tumors generally contain heterogeneous populations of cancer cells with variable phenotypes and likely become a target of different types of effector cells, effector molecules, or therapeutic reagents for immunotherapy. 56 Therefore, induction of CD11b + Ly6G + cell-mediated cytolysis by dsRNA treatment in combination with other therapies using monoclonal Abs targeting cancer-associated molecules, immune checkpoint inhibitors, or CD8 + T cell-based therapy may be beneficial in some patients. We propose that the formation of a tumorsuppressive microenvironment is fundamentally induced by the TLR3/TICAM-1 pathway in myeloid cells, and this pathway is a promising target for the development of cancer immunotherapy.
Materials and Methods
Mice and tumor cells. Inbred C57BL/6 wild-type (B6 WT) mice were purchased from Clea Japan (Tokyo, Japan). TICAM-1 − / − and MAVS (IPS-1)
mice were generated in our laboratory. 5, 57 IFNAR1 − / − mice were obtained from Dr. T Taniguchi (University of Tokyo, Tokyo, Japan). Mice (aged 6 to 10 weeks) were used in all experiments and maintained under specific pathogen-free conditions. The protocol was approved by the Committee on the Ethics of Animal Experiments in the Animal Safety Center, Hokkaido University, Japan. All mice were used according to the guidelines of the institutional animal care and use committee of Hokkaido University, who approved this study as ID number 08-0290 and 13-0043. EL4 cells were obtained from Dr. Sato (Sapporo Medical University, Sapporo, Japan). The B16D8 cell line was established in our laboratory as a subline of B16 melanoma.
58 3LL, MC38, and C1498 cell lines were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA). EL4, B16D8, 3LL, and C1498 cells were cultured at 37°C under 5% CO 2 in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ ml streptomycin. MC38 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 50 μM 2-ME, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies, Carlsbad, CA, USA). Immunohistochemistry. Tumors were fixed with 10% neutralized buffered formalin at 4°C for 4 h, equilibrated with 15% sucrose in PBS( − ) for 1 h, and then with 30% sucrose in PBS( − ) for 16-18 h. Tissue samples were embedded in Tissue Tek O.C.T compound (Sakura Finetek Japan, Tokyo, Japan), frozen, and stored at −80°C until use. The tissue block was cut at a thickness of 10 μm. For the TUNEL assay, tumor sections were stained using the In Situ Cell Death Detection Kit, Fluorescein (Roche, Basel, Switzerland). For detection of caspase-3 activation, Abs against cleaved caspase-3 (Asp175) (5A1E) and an Alexa488-antirabbit IgG secondary Ab (Life Technologies) were used.
Cell isolation and culture. CD11b 
Ly6G
+ cells were isolated from a singlecell suspension from the spleen of polyI:C-or PBS-injected mice by using a biotin-conjugated anti-Ly6G monoclonal Ab (1A8) (Biolegend, San Diego, CA, USA) and Streptavidin Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. In these purification steps, two rounds of positive selection were performed to increase purity. We routinely prepared Ly6G Figure 2) . Isolated CD11b + Ly6G + cells were cultured in Opti-MEM (Life Technologies) supplemented with or without 0.5% FBS for in vitro polyI:C stimulation or cytotoxicity assays, respectively. To inhibit iNOS activity, EL4 tumorbearing mice were injected i.p. with L-NAME (1.5 mg/head) or L-NIL (0.5 mg/head) 5 h after polyI:C treatment. After 2 h, CD11b + Ly6G + cells were isolated from the spleen and used for the cytotoxicity assay.
Flow cytometry. Single-cell suspensions isolated from tumors or spleens were stained with fluorescent dye-labeled Abs after blockade with an anti-CD16/32 Ab (93). The following Abs were used: FITC-anti-CD11b (M1/70), PE-anti-GR1 (RB6-8C5), APC-or FITC-anti-Ly6G (1A8), FITC-anti-CD11c (N418), PE-or APC-anti-F4/80 (BM8), PE-anti-NK1.1 (PK136), PE-anti-CD49b (DX5), PE-antiCD3e (145-2C11), FITC-anti-CD4 (GK1.5), FITC-anti-CD8a (53-6.7), and PE-anti-CD19 (MB19-1) (eBioscience, San Diego, CA, USA or Biolegend). For detection of intracellular ROS/RNS, fluorescent probes were applied. Cells were stained with 5 μM APF, 5 μM HPF (SEKISUI Medical, Tokyo, Japan), and 5 μM BES-H 2 O 2 -Ac (Wako, Osaka, Japan) at 25°C for 15 min, followed by staining with an APC-anti-Ly6G Ab (1A8) at 25°C for 15 min. Samples were analyzed by a FACS Calibur or FACS Aria II (BD Biosciences, San Jose, CA, USA); data analysis was performed using Flow Jo (Tree Star, Ashland, OR, USA).
In vivo depletion. The in vivo depletion of cells was achieved by i.p. injection of ascites containing monoclonal Abs against CD8β (53-6.7), CD4 (GK1.5), NK1.1 (PK136), or Gr1 (RB6-8C5). For Ly6G + cell depletion, 150 μg of Ultra-LEAF purified anti-mouse Ly6G Ab (1A8) (Biolegend) was injected i.p. into mice. Ultra-LEAF purified rat IgG2a (Biolegend) was used as an isotype matched control Ab. Antibodies were injected 1 day before the polyI:C treatment. Depletion of cells in tumor-bearing mice was confirmed by flow cytometry of spleen and tumor cell suspensions.
Immunoblotting. Tumors excised from mice or cancer cell lines were lysed in 1% NP-40, 10 mM Tris-HCl (pH 7.2) supplemented with a complete protease inhibitor cocktail (Roche) and incubated for 30 min on ice. The lysate was centrifuged at 15 000 r.p.m. for 10 min to remove cell debris. The supernatant was mixed with a 2 × SDS-PAGE sample buffer and heated at 85°C for 5 min. Samples were stored at − 30°C until use. An equal amount (50 μg) of protein was analyzed by SDS-PAGE (12% acrylamide). Abs against cleaved caspase-3 (Asp175) (5A1E), cleaved caspase-8 (Asp387), full-length caspase-9, full-length caspase-12 (Cell Signaling Technology, Danvers, MA, USA), and HRP-conjugated goat antirabbit IgG Ab (Life Technologies) were used for detection of caspases.
Cytotoxic activity assay. Cytotoxic activity of CD11b + Ly6G + cells was measured by the following procedure. EL4 cells (1 × 10 6 ) were incubated in 1 ml of 0.5 μM carboxyfluorescein diacetate succinimidyl ester (CFSE) in PBS at 37°C for 15 min. After washing 2 times with RPMI-1640 supplemented with 10% FBS, CFSE-labeled EL4 cells were cultured in Opti-MEM (Life Technologies) containing 10 ng/ml recombinant mouse GM-CSF (Peprotech, Rocky Hill, NJ, USA) for 4 h. Complementary DNA (cDNA) was synthesized using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed with Power SYBR Green PCR Master Mix (Applied Biosystems) and a StepOne Real-Time PCR System (Applied Biosystems). Expression of the cytokine genes was normalized to the expression of mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH). We used following primer pairs: mouse GAPDH forward, 5′-GCCTGGAGAAACCTGCCA-3′, GAPDH reverse, 5′-CCCTCAGATGCCTGCTTCA-3′; mouse iNOS (NOS2) forward, 5′-CAGCTGGGCTGTACAAACCTTC-3′, mouse iNOS (NOS2) reverse, 5′-CATT GGAAGTGAAGCGTTTCG-3′; mouse NOX2 (pg91phox, Cybb) forward, 5′-TGC AGTGCTATCATCCAAGC-3′, mouse NOX2 (pg91phox, Cybb) reverse, 5′-CTTT CTCAGGGGTTCCAGTG-3′. Data were analyzed by the ΔΔCt method.
Statistical analysis. Statistically significant differences between two groups were determined using Student's t-test.
